Study M093
Study name | Xia XT 2016 |
Title | [Discovering potential biomarkers of depression and drug intervention of paroxetine based on 1H NMR metabolomics] |
Overall design | The purpose of this study was to find potential biomarkers in the serum of patients with depression and provide the basis for clinical diagnosis of depression. Patients of severe depression (depression group, n = 16) were selected according to the inclusion criteria and healthy people (control group, n = 16) were used in the control group. The depression patients took paroxetine (20 mg/d) for two weeks. Serum samples from depression group, control group, and paroxetine group (n = 16 in each group) were used for metabonomic analysis. |
Study Type | Type1; Type2; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | CCMD-3 diagnosed MDD, HAMD-17 for severe depression symptom |
Sample size | 32 |
Tissue | Peripheral; Blood; Serum; |
Platform | NMR; NMR: Bruker AVANCE III 600 spectrometer (Bruker Biospin, Rheinstetten, Germany); |
PMID | |
DOI | |
Citation | Xia XT, Sun N, Liu CC, et al. [Discovering potential biomarkers of depression and drug intervention of paroxetine based on 1H NMR metabolomics]. Yao Xue Xue Bao 2016;51(4):595-9. (Article in Chinese) |
Metabolite |
